JP4174422B2 - 発現ツールとしてのｆｋｂｐシャペロンの使用 - Google Patents

発現ツールとしてのｆｋｂｐシャペロンの使用 Download PDF

Info

Publication number
JP4174422B2
JP4174422B2 JP2003507263A JP2003507263A JP4174422B2 JP 4174422 B2 JP4174422 B2 JP 4174422B2 JP 2003507263 A JP2003507263 A JP 2003507263A JP 2003507263 A JP2003507263 A JP 2003507263A JP 4174422 B2 JP4174422 B2 JP 4174422B2
Authority
JP
Japan
Prior art keywords
protein
fusion protein
fkpa
polypeptide
chaperone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003507263A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004535195A5 (https=
JP2004535195A (ja
Inventor
ショルツ，クリスチャン
アンドレス，ヘルベルト
ファーツ，エルケ
エンゲル，アルフレート
シュミット，ウルバーン
バツァルスウレン，アリウナ
シャールシュミット，ペーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2004535195A publication Critical patent/JP2004535195A/ja
Publication of JP2004535195A5 publication Critical patent/JP2004535195A5/ja
Application granted granted Critical
Publication of JP4174422B2 publication Critical patent/JP4174422B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
JP2003507263A 2001-06-22 2002-06-24 発現ツールとしてのｆｋｂｐシャペロンの使用 Expired - Fee Related JP4174422B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01115225 2001-06-22
EP01120939 2001-08-31
PCT/EP2002/006957 WO2003000878A2 (en) 2001-06-22 2002-06-24 Use of fkbp chaperones as expression tool

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006326846A Division JP4309910B2 (ja) 2001-06-22 2006-12-04 発現ツールとしてのｆｋｂｐシャペロンの使用

Publications (3)

Publication Number Publication Date
JP2004535195A JP2004535195A (ja) 2004-11-25
JP2004535195A5 JP2004535195A5 (https=) 2005-08-25
JP4174422B2 true JP4174422B2 (ja) 2008-10-29

Family

ID=26076626

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2003507263A Expired - Fee Related JP4174422B2 (ja) 2001-06-22 2002-06-24 発現ツールとしてのｆｋｂｐシャペロンの使用
JP2003507262A Expired - Fee Related JP4262594B2 (ja) 2001-06-22 2002-06-24 レトロウイルス表面糖タンパク質を含む可溶性複合体
JP2006326846A Expired - Fee Related JP4309910B2 (ja) 2001-06-22 2006-12-04 発現ツールとしてのｆｋｂｐシャペロンの使用
JP2007183508A Expired - Fee Related JP4320351B2 (ja) 2001-06-22 2007-07-12 レトロウイルス表面糖タンパク質を含む可溶性複合体
JP2008286959A Withdrawn JP2009102320A (ja) 2001-06-22 2008-11-07 レトロウイルス表面糖タンパク質を含む可溶性複合体
JP2009025509A Expired - Fee Related JP4523660B2 (ja) 2001-06-22 2009-02-06 発現ツールとしてのｆｋｂｐシャペロンの使用

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2003507262A Expired - Fee Related JP4262594B2 (ja) 2001-06-22 2002-06-24 レトロウイルス表面糖タンパク質を含む可溶性複合体
JP2006326846A Expired - Fee Related JP4309910B2 (ja) 2001-06-22 2006-12-04 発現ツールとしてのｆｋｂｐシャペロンの使用
JP2007183508A Expired - Fee Related JP4320351B2 (ja) 2001-06-22 2007-07-12 レトロウイルス表面糖タンパク質を含む可溶性複合体
JP2008286959A Withdrawn JP2009102320A (ja) 2001-06-22 2008-11-07 レトロウイルス表面糖タンパク質を含む可溶性複合体
JP2009025509A Expired - Fee Related JP4523660B2 (ja) 2001-06-22 2009-02-06 発現ツールとしてのｆｋｂｐシャペロンの使用

Country Status (15)

Country Link
US (2) US7244819B2 (https=)
EP (3) EP2267452B8 (https=)
JP (6) JP4174422B2 (https=)
KR (2) KR100702373B1 (https=)
CN (1) CN100510068C (https=)
AT (2) ATE522603T1 (https=)
AU (2) AU2002317841A1 (https=)
BR (1) BRPI0210598B8 (https=)
CA (3) CA2770453C (https=)
DE (1) DE60233942D1 (https=)
DK (2) DK1402015T3 (https=)
ES (3) ES2391623T3 (https=)
MX (1) MXPA03011455A (https=)
PL (2) PL215170B1 (https=)
WO (2) WO2003000877A2 (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03011455A (es) * 2001-06-22 2004-04-05 Hoffmann La Roche Complejo soluble que comprende glucoproteina de superficie retroviral.
EP1516928B1 (en) * 2002-06-25 2010-02-17 Sekisui Chemical Co., Ltd. Expression vector, host, fused protein, process for producing fused protein and process for producing protein
DK1567195T3 (da) * 2002-11-26 2011-02-14 Upfront Chromatography As Dendrimerkonjugater til selektiv opløsning af proteinaggregater
AU2004230803A1 (en) * 2003-04-18 2004-10-28 Chiba, Joe Immunogen, composition for immunological use and process for producing antibody using the same
US9057061B2 (en) * 2003-12-23 2015-06-16 Novozymes Biopharma Dk A/S Gene expression technique
US7604935B2 (en) 2005-10-26 2009-10-20 Roche Diagnostics Operations, Inc. Soluble rubella E1 envelope protein variants
WO2007077008A1 (en) 2006-01-03 2007-07-12 Roche Diagnostics Gmbh Chimaeric fusion protein with superior chaperone and folding activities
WO2007141650A2 (en) * 2006-01-17 2007-12-13 Instituto De Medicina Molecular Compositions and methods for diagnosing hiv-2 infection
JP2009536958A (ja) 2006-05-11 2009-10-22 ベクトン・ディキンソン・アンド・カンパニー 細胞からのタンパク質抽出方法
GB0611405D0 (en) 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
ATE529436T1 (de) 2007-04-20 2011-11-15 Hoffmann La Roche Erkennung von primären infektionen mit krankheitserregern
WO2009031852A2 (en) * 2007-09-06 2009-03-12 Korea University Industry and Academy Cooperation Foundation Preparation method of recombinant protein by use of a fusion expression partner
US9207240B2 (en) 2007-11-14 2015-12-08 Arbor Vita Corporation Method of efficient extraction of protein from cells
ES2450998T3 (es) 2007-12-13 2014-03-26 F. Hoffmann-La Roche Ag Nuevas variantes de proteína de cubierta E1 de rubéola y su utilización en la detección de anticuerpos anti-rubéola
EP2127678A1 (en) 2008-05-26 2009-12-02 Roche Diagnostics GmbH SlpA as a tool for recombinant protein and enzyme technology
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
AU2012212047A1 (en) * 2011-02-03 2013-08-22 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
AR086250A1 (es) 2011-05-05 2013-11-27 Hoffmann La Roche Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2617731A1 (en) 2012-01-19 2013-07-24 Roche Diagnostics GmbH Soluble immunoreactive Treponema pallidum TpN47 antigens
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2706115A1 (en) 2012-09-06 2014-03-12 Roche Diagnostics GmbH Chaperone-chaperone fusion polypeptides for reduction of interference and stabilization of immunoassays
AR093778A1 (es) 2012-11-08 2015-06-24 Hoffmann La Roche PROTEINAS LIGANTES DE ANTIGENO ANTI-HER3/HER4 DE UNION A LA HORQUILLA b DE HER3 Y A LA HORQUILLA b DE HER4
MA38165A1 (fr) 2012-11-08 2018-07-31 Hoffmann La Roche Protéines de liaison à l'antigène her3 se liant à l'épingle à cheveux beta de her3
ES2603589T3 (es) 2012-11-08 2017-02-28 F. Hoffmann-La Roche Ag Ácidos nucleicos que codifican polipéptidos quiméricos para la identificación sistemática de bibliotecas
EP2827146A1 (en) 2013-07-18 2015-01-21 Roche Diagnostics GmbH Vibrio cholerae lipoprotein 15 (Lp15) variants as anti-interference additive in TpN17-based immunoassays for detection of anti-Treponema antibodies
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
WO2015044083A1 (en) * 2013-09-27 2015-04-02 F. Hoffmann-La Roche Ag Thermus thermophilus slyd fkbp domain specific antibodies
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP2913338A1 (en) 2014-02-28 2015-09-02 Roche Diagniostics GmbH Soluable and immunoreactive variants of HTLV capsid antigen p24
JP2015215244A (ja) * 2014-05-12 2015-12-03 富士レビオ株式会社 免疫測定における抗ｈｔｌｖ抗体の検出感度を向上させる方法
MX2016014416A (es) 2014-05-14 2017-02-23 Hoffmann La Roche Anticuerpos anti-her3 que se unen a la horquilla beta de her3.
BR112016025056A2 (pt) 2014-05-14 2018-02-20 F. Hoffmann-La Roche Ag uso de pelo menos um polipeptídeo, anticorpo biespecífico, anticorpo biespecífico isolado, anticorpo her3/her2 biespecífico, célula hospedeira, método de produção do anticorpo biespecífico her3/her2, imunoconjugado e formulação farmacêutica
CN107532190B (zh) 2014-12-01 2021-07-09 菲尼克斯公司 用于肽生产的融合伴侣
CA2974343A1 (en) * 2015-02-13 2016-08-18 Sekisui Chemical Co., Ltd. Nucleic acid, fusion protein, recombined cell, and isoprene or cyclic terpene production method
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
JP6967002B2 (ja) * 2015-12-15 2021-11-17 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft トランスグルタミナーゼ認識部位を有するｆｋｂｐドメイン
ES2796479T3 (es) 2016-05-31 2020-11-27 Hoffmann La Roche Procedimiento de pretratamiento para la detección rápida del antígeno central del VHC
JP2019523863A (ja) 2016-05-31 2019-08-29 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ウイルス抗原の血清学的検出方法
EP3472322B1 (en) * 2016-06-20 2022-01-05 MetGen Oy Method for obtaining active insoluble xylose isomerase
JP7068323B2 (ja) 2017-02-02 2022-05-16 エフ．ホフマン－ラ ロシュ アーゲー 少なくとも２種のペグ化された分析物特異的結合剤を使用する免疫アッセイ
CN110709410B (zh) 2017-04-26 2024-07-02 豪夫迈·罗氏有限公司 可溶性和免疫反应性寨卡病毒ns1多肽
CN110996986B (zh) 2017-07-27 2024-07-19 豪夫迈·罗氏有限公司 Hcv抗原的多表位融合蛋白及其用途
CN110066343B (zh) * 2019-05-23 2021-04-09 北京新创生物工程有限公司 一种用于检测hiv新发感染的重组抗原及其应用
CN115843334B (zh) 2020-04-23 2026-01-13 豪夫迈·罗氏有限公司 用于抗体免疫测定的冠状核衣壳抗原
WO2023012321A1 (en) 2021-08-06 2023-02-09 Roche Diagnostics Gmbh Chimeric igg-fc-binding ligand polypeptide and uses thereof for igg affinity purification
US20250298022A1 (en) 2022-05-03 2025-09-25 Roche Diagnostics Operations, Inc. Hiv gp41 variants for immunodiagnostic assays
WO2025098623A1 (en) 2023-11-09 2025-05-15 Roche Diagnostics Gmbh Transglutaminase substrates for labeling

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2095818B (en) 1981-03-27 1985-10-02 Exxon Research Engineering Co Staged adsorption/resorption heat pump
US4735896A (en) 1986-03-04 1988-04-05 United Biomedical, Inc. Synthetic peptide and process of using same for the detection and diagnosis of AIDS and pre-AIDS conditions
US4879212A (en) 1986-04-02 1989-11-07 United Biomedical Inc. Peptide composition and method for the detection of antibodies to HTLV-III
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
DE3705686C2 (de) 1987-02-23 1995-11-30 Boehringer Mannheim Gmbh Verfahren zur Bestimmung von Antikörpern
NZ224663A (en) 1987-05-28 1990-11-27 Amrad Corp Ltd Fusion proteins containing glutathione-s-transferase and expression of foreign polypeptides using glutathione-s-transferase encoding vectors
SE8704185L (sv) 1987-10-28 1989-04-29 Ferring Ab Nya peptider, artificiella antigener och immunoanalystestsatser
CA2003383A1 (en) * 1988-11-23 1990-05-23 Sushil G. Devare Synthetic dna derived recombinant hiv antigens
ATE160358T1 (de) 1991-06-14 1997-12-15 St Vincents Inst Med Res Detektion des immunschwäche-virus aus felis
WO1993013200A1 (en) * 1991-12-20 1993-07-08 Novo Nordisk A/S A process for the preparation of lipase
JP2001504572A (ja) 1992-04-09 2001-04-03 アボツト・ラボラトリーズ Ｈｉｖ抗原及びｈｉｖ抗体を検出するためのアッセイ
WO1993025533A1 (en) 1992-06-05 1993-12-23 Abbott Laboratories Methods and reagents for the determination of immunosuppressive agents
ATE195347T1 (de) 1992-10-02 2000-08-15 Res Corp Technologies Inc Methoden der erhöhung der sekretion von überexpremierten proteinen
US5459051A (en) 1993-03-26 1995-10-17 Celtrix Pharmaceuticals, Inc. Methods and vectors for over-expression of ubiquitin fusion proteins in host cells
DE4428705A1 (de) * 1994-08-12 1996-02-15 Boehringer Mannheim Gmbh Rekombinantes Antigen aus der NS3-Region des Hepatitis C Virus
AU3968595A (en) 1994-10-25 1996-05-15 Board Of Trustees Of The Leland Stanford Junior University Conditional transformation of genetically engineered cells
WO1996041865A1 (en) 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Rapamcycin-based regulation of biological events
WO1997010502A1 (en) 1995-09-15 1997-03-20 Merck & Co., Inc. A high throughput assay using fusion proteins
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
GB9614114D0 (en) 1996-07-05 1996-09-04 Amcor Packaging Uk Ltd New packages
JP2001501093A (ja) 1996-09-26 2001-01-30 メディカル リサーチ カウンシル シャペロン断片
US6225082B1 (en) * 1997-05-09 2001-05-01 Research Corporation Technologies, Inc. Myelin basic protein MRNA transport and translation enhancer sequences
US5989868A (en) * 1997-09-12 1999-11-23 The Board Of Regents Of The University Of Oklahoma Fusion protein systems designed to increase soluble cytoplasmic expression of heterologous proteins in esherichia coli
JP2002508971A (ja) 1998-01-15 2002-03-26 アリアド・ジーン・セラピューティクス・インコーポレーテッド 多量体キメラ蛋白質を使用する生物学的イベントの調節
DE19913117A1 (de) * 1998-05-06 1999-11-11 Roche Diagnostics Gmbh Entstörung durch Rheumafaktoren
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
ATE473755T1 (de) 1998-10-02 2010-07-15 Rhein Biotech Proz & Prod Gmbh Methode zur herstellung von (poly)peptiden unter verwendung von verkürzten varianten von sv40 large t antigen mit einem intakten n terminus
EP1127140A2 (en) 1998-11-06 2001-08-29 President And Fellows Of Harvard College Fk506-based regulation of biological events
AU3305100A (en) 1999-03-17 2000-10-04 Medical Research Council Method for refolding molecules of polypeptides containing ig domains
AU4933200A (en) 1999-05-14 2000-12-05 Medical Research Council Oligomeric chaperone proteins
GB9913437D0 (en) 1999-06-09 1999-08-11 Medical Res Council Fusion proteins
EP1077263A1 (de) * 1999-07-29 2001-02-21 F.Hoffmann-La Roche Ag Verfahren zur Herstellung von natürlich gefalteten und sekretierten Proteinen durch Co-Sekretion von Chaperonen
CA2403718A1 (en) * 2000-03-17 2001-09-27 Panacos Pharmaceuticals, Inc. A method for generating immunogens that elicit neutralizing antibodies against fusion-active regions of hiv envelope proteins
JP2002262883A (ja) * 2001-03-13 2002-09-17 Sekisui Chem Co Ltd モノクローナル抗体の製造方法
MXPA03011455A (es) * 2001-06-22 2004-04-05 Hoffmann La Roche Complejo soluble que comprende glucoproteina de superficie retroviral.

Also Published As

Publication number Publication date
BRPI0210598B1 (pt) 2018-11-13
KR20040010774A (ko) 2004-01-31
US20030096352A1 (en) 2003-05-22
DK2267452T3 (da) 2012-10-29
US8426167B2 (en) 2013-04-23
HK1068918A1 (zh) 2005-05-06
EP1402041B1 (en) 2009-10-07
ATE522603T1 (de) 2011-09-15
EP1402015B1 (en) 2011-08-31
DK1402015T3 (da) 2011-12-05
JP4523660B2 (ja) 2010-08-11
EP2267452A1 (en) 2010-12-29
KR100702373B1 (ko) 2007-04-02
PL367679A1 (en) 2005-03-07
JP4309910B2 (ja) 2009-08-05
JP4320351B2 (ja) 2009-08-26
CN100510068C (zh) 2009-07-08
AU2002325265B2 (en) 2006-10-19
MXPA03011455A (es) 2004-04-05
CN1524123A (zh) 2004-08-25
ATE445016T1 (de) 2009-10-15
KR100611545B1 (ko) 2006-08-10
EP1402041A2 (en) 2004-03-31
DE60233942D1 (de) 2009-11-19
ES2372031T3 (es) 2012-01-13
US7244819B2 (en) 2007-07-17
PL218245B1 (pl) 2014-10-31
BR0210598A (pt) 2004-07-20
EP2267452B8 (en) 2012-11-14
KR20060027871A (ko) 2006-03-28
CA2450476A1 (en) 2003-01-03
US20090028893A1 (en) 2009-01-29
WO2003000877A2 (en) 2003-01-03
AU2002317841A1 (en) 2003-01-08
JP2004534831A (ja) 2004-11-18
EP1402015A2 (en) 2004-03-31
PL215170B1 (pl) 2013-10-31
ES2391623T3 (es) 2012-11-28
JP2004535195A (ja) 2004-11-25
WO2003000878A3 (en) 2003-10-09
CA2449747A1 (en) 2003-01-03
CA2770453C (en) 2014-12-09
PL397776A1 (pl) 2012-07-16
WO2003000877A3 (en) 2003-10-30
JP2009102320A (ja) 2009-05-14
JP2007322436A (ja) 2007-12-13
ES2333108T3 (es) 2010-02-17
CA2449747C (en) 2010-04-13
WO2003000878A2 (en) 2003-01-03
JP2009100770A (ja) 2009-05-14
EP2267452B1 (en) 2012-07-25
CA2450476C (en) 2012-05-15
CA2770453A1 (en) 2003-01-03
BRPI0210598B8 (pt) 2021-05-25
JP4262594B2 (ja) 2009-05-13
JP2007125026A (ja) 2007-05-24

Similar Documents

Publication Publication Date Title
JP4174422B2 (ja) 発現ツールとしてのｆｋｂｐシャペロンの使用
US8247206B2 (en) Fusion protein comprising an Escherichia coli chaperone protein and a human chaperone protein
KR100553510B1 (ko) 항융합형성 펩티드의 재조합 제조 방법
CN101591665B (zh) 作为重组蛋白和酶技术的工具的SlpA
JP4504014B2 (ja) インスリン分泌性ｇｌｐ−１（７−３６）ポリペプチドおよび／またはｇｌｐ−１類似体を生成する方法
CN104583408B (zh) 用于降低免疫测定的干扰且稳定免疫测定的分子伴侣‑分子伴侣融合多肽
JP2024516907A (ja) 向上したタンパク質精製
JP5020487B2 (ja) 融合タンパク質発現用新規ｄｎａ及び該ｄｎａを用いたタンパク質の製造方法
HK1128727B (en) Chimaeric fusion protein with superior chaperone and folding activities
WO2026007971A1 (zh) 重组抗原、含其的试剂及用途
JPH11127858A (ja) ウマ動脈炎ウイルスの抗原性を有するポリペプチドと該ウイルス感染症の診断法
HK1138620B (en) Slpa as a tool for recombinant protein and enzyme technology

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060607

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060904

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080226

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080326

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080808

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080818

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4174422

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110822

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110822

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120822

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120822

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130822

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees